Triplet Therapy for High-Risk Chronic Lymphocytic Leukemia: An Update

First-line therapy with ibrutinib, venetoclax and obinutuzumab provided high response rates in previously untreated patients with CLL and TP53 mutation and del(17p).

TP53-aberrant chronic lymphocytic leukemia (CLL) responds to Bruton tyrosine kinase (BTK) inhibitors and to venetoclax plus an anti-CD20 antibody or a BTK inhibitor, although the durations of response are shorter than among other CLL subtypes.

In the prior industry-sponsored, multicenter, open-label CLL2-GIVe trial (NEJM JW Oncol Hematol 2022 Mar 24 and Blood 2022; 139:1318), treatment with obinutuzumab, ibrutinib, and venetoclax induced high response rates in previously untreated patients with CLL and del(17p) and/or TP53 mutation at 24 months.

Investigators now report a final analysis of the phase 2 CLL2-GIVe trial after a median observation time of 38.5 months. Among 41 patients, 58% had both TP53 mutation and del(17p), 37% had TP53 mutati…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Triplet Therapy for High-Risk Chronic Lymphocytic Leukemia: An Update

Topics

Reviewing Author